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The herpes simplex virus 2 dl5-29 replication-defective mutant virus has been shown to induce protective immunity in mice and both
prophylactic and therapeutic immunity in guinea pigs. In an attempt to improve the efficacy of dl5-29 we disrupted its UL41 gene, producing the
triple mutant virus dl5-29-41L. dl5-29-41L has a decreased ability to inhibit host cell protein synthesis and a reduced cytopathic effect on cultured
cells. When used to immunize mice, dl5-29-41L elicited significantly stronger neutralizing antibody responses and significantly stronger CD4+
and CD8+ cellular immune responses than dl5-29. The enhanced immune responses corresponded with increased protective capacity in a murine
model of genital herpes. The protective immunity elicited by either virus was very durable, protecting mice for at least 7 months. Furthermore, we
show that cell lysate preparations of both viruses were significantly more efficacious than the corresponding extracellular virus preparations.
© 2007 Elsevier Inc. All rights reserved.Keywords: Replication-defective virus; Herpes; HSV; VaccineIntroduction
Herpes simplex virus 2 (HSV-2) is a common human
pathogen, infecting approximately 17% of the adult population
in the US (Xu et al., 2006), for which there is currently no
broadly effective vaccine. HSV-2 initiates infection in the
epithelium and then quickly spreads to and establishes latency
within local sensory neurons. The latent virus can later reactivate
to cause disease, a process that continues throughout the life
span of the host. A variety of clinical syndromes are caused by
HSV infection, including life-threatening infections of neonates
and immunocompromised individuals such as those with HIV/
AIDS. There is a growing body of epidemiological and bio-
logical evidence that HSV-2 infection is strongly linked with the⁎ Corresponding author. Department of Microbiology and Molecular
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doi:10.1016/j.virol.2007.10.014HIV epidemic (Freeman et al., 2006). It has been shown that a
preexisting HSV-2 infection greatly increases the likelihood of
HIV-1 acquisition (Reynolds et al., 2003; Wald and Link, 2002),
and individuals co-infected with HSV-2 and HIV-1 tend to show
higher HIV-1 viral loads (Schacker et al., 2002). Perhaps most
notably, a recent study has shown that an anti-HSV therapeutic
can reduce both the genital and plasma HIV-1 RNA levels in
dual infected individuals (Nagot et al., 2007), and this reduction
in HIV-1 viral RNA loadsmay lead to reduced transmission rates
and decrease progression to AIDS. These studies suggest that an
effective HSV-2 vaccine would not only be useful against HSV-2
disease, but also may provide an effective means of reducing
HIV-1 infection. The large disease burden caused by HSV-2 and
the contributory role of genital HSV-2 disease to the HIV/AIDS
pandemic drive the efforts to find an effective HSV-2 vaccine
(Jones and Knipe, 2003).
Various approaches have been undertaken to produce a
vaccine against HSV-2, yet only one has shown any protective
efficacy in humans (Stanberry et al., 2002) and none has shown
efficacy within the general population (Corey et al., 1999;
Fig. 1. Diagram of the dl5-29-41L genome. Line A represents the dl5-29
genome containing deletions in the UL5 and UL29 genes. Line B shows an
expanded view of the UL41 gene and bounding sequences. Line C indicates the
section of UL41 that was removed by SacII digestion. Line D illustrates the
mammalian LacZ expression cassette that was inserted into the 518 bp deletion
within UL41 created by the SacII deletion. Nucleotide numbers correspond to
the HSV-2 HG-52 viral genome.
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It is likely that an effective vaccine against HSV-2 will be
required to elicit both humoral as well as cellular immunity,
while retaining a high safety profile that would allow for
vaccination of individuals who are or may become immuno-
compromised. Replication-defective viruses may possess both
of these desired properties (Dudek and Knipe, 2006).
The HSV-2 replication-defective mutant virus dl5-29 con-
tains deletions of both the UL5 and UL29 genes. The UL5 gene
encodes a component of the viral helicase–primase complex and
UL29 encodes ICP8, the viral single-stranded DNA binding
protein. Both of these gene products are essential for viral
DNA replication and deletion of either gene renders a virus
replication-defective. Therefore, dl5-29 can infect a normal cell
and express a vast majority of viral proteins, but it is unable to
replicate its genome and produce infectious progeny so the viral
life cycle is interrupted (Da Costa et al., 2000). dl5-29 has
previously been shown to induce protective immunity in mice
(Da Costa et al., 1999) and has shown both protective and
therapeutic efficacy in guinea pigs (Hoshino et al., 2005). Based
on the immunogenic and protection studies in mice and guinea
pigs, dl5-29 has been chosen to enter clinical trials. We have
undertaken studies to further modify dl5-29 genetically because
comparison of additional viral mutants may not only provide
better vaccine candidates but may also provide information that
helps define the mechanisms of immune protection and immune
correlates.
HSV-1 and HSV-2 both contain a gene, UL41, which
encodes the virion host shut-off (vhs) function. This gene
product causes the degradation of both host and viral mRNA,
leading to the shutdown of host cell protein synthesis. Early in
infection the high level of viral transcription overcomes this
effect, allowing the virus to continue replicating, while at late
time points during the replication cycle the vhs activity may be
inhibited by its binding to VP16 (Lam et al., 1996). Disruption
of UL41 has been shown to increase the immunogenicity of
replication-competent (Walker and Leib, 1998) and replication-
defective HSV-1 viruses (Geiss et al., 2000), but the
immunogenicity of UL41 disrupted HSV-2 mutant viruses has
not been determined. HSV-2 is known to have a significantly
greater effect on host cell protein synthesis than that of HSV-1
(Fenwick et al., 1979) and this effect has been shown to be vhs-
specific (Everly and Read, 1997). Therefore, we wished to
determine the effect of disrupting UL41 on viral immunogenic-
ity in the context of a replication-defective HSV-2 mutant virus,
the dl5-29 candidate vaccine virus. Here we characterize this
new virus, dl5-29-41L, and compare its immunogenicity and
protective capacity with that of dl5-29 in a murine model.
Results
Construction and characterization of the dl5-29-41L mutant
virus
To generate a triple mutant virus with the UL41 gene
inactivated, we inserted a LacZ expression cassette into a
SacII–SacII deletion within the UL41 gene locus in a plasmidand then introduced the insertion into the dl5-29 viral genome
via homologous recombination as described previously (Da
Costa et al., 1997) (Fig. 1). Similar disruptions of the UL41 gene
have been shown to disrupt Vhs function (Strelow and Leib,
1995).
To determine if disruption ofUL41 in our dl5-29 mutant virus
affects the ability of the virus to shut off host protein synthesis,
we examined host and viral protein synthesis in Vero and mouse
embryo fibroblasts (MEF) cell lines by mock-infecting or
infecting with dl5-29, dl5-29-41L or the wild-type HSV-2 strain
186 syn+-1 virus (Fig. 2). Cells infected with dl5-29-41L
showed a total host protein expression pattern most similar to
that of mock-infected cells (Fig. 2, lanes 1 and 5; illustrative host
protein bands are marked by asterisks), while still producing
HSV-2 viral proteins similar in both specificity and intensity to
that of dl5-29 (Fig. 2, lanes 3 and 7; representative viral bands
marked by arrows). The lack of host cell protein shut-off was
also apparent as delayed and decreased cytopathic effect on
infected cells during a productive infection of the V5-29
complementing cell line (data not shown).
dl5-29-41L elicits stronger humoral immune responses than
dl5-29
To compare immune responses elicited by the two viruses,
we immunized Balb/c mice subcutaneously with two doses
of 104, 105 or 106 pfu of dl5-29 or dl5-29-41L at an interval of
3 weeks. At 7 days post-immunization mice were bled via the
tail vein, and serum samples from each immunization group
were collected and pooled.
HSV-2 specific antibodies
The total serum IgG response against HSV-2 antigen was
measured via ELISA using sera pooled from each immunization
group of eight mice (Table 1). As an extracellular supernatant
viral immunogen preparation, dl5-29-41L elicited 2-fold higher
total IgG titers than dl5-29, although the antibody titers
observed when mice were immunized with whole cell lysate
viral immunogen preparations of either dl5-29 or dl5-29-41L
Table 1
Humoral immune responses induced by dl5-29 and dl5-29-41L
Dose
(pfu)
Total serum IgG titer a Neutralizing Ab titer b
Ex. cell c Lysate d Ex. cell c Lysate d
dl5-29 104 ≤50 200 b25 b25
105 ≤50 800 b25 b25
106 200 12,800 25 25
dl5-29-41L 104 ≤50 200 b25 b25
105 200 800 b25 b25
106 400 12,800 200 200
a Measured by ELISA against total HSV-2 G strain virus antigen.
b Measured by plaque reduction assay against HSV-2 G strain.
c Extracellular supernatant virus immunogen.
d Cell lysate virus immunogen.
Fig. 2. Mutant dl5-29-41L has a reduced ability to inhibit host cell protein
synthesis. Vero cells (left panel) and mouse embryo fibroblasts (right panel)
were either mock infected (lanes 1, 5) or infected with wild-type HSV-2 (lanes
2, 6), dl5-29 (lanes 3, 7) or dl5-29-41L (lanes 4, 8) viruses at an MOI of 10 for
6 h. At 30 min before harvesting cells were labeled with 35S-methionine.
Proteins were resolved on a 9.25% DATD cross-linked gel and the gel was
subjected to audioradiography. The resulting autoradiogram is shown. Major
host protein bands are denoted by asterisks while representative viral proteins
are marked by arrows.
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titers elicited in mice immunized with cell lysate immunogen
(12,800 for either dl5-29 or dl5-29-41L) over those elicited by
supernatant viruses (200 for dl5-29 and 400 for dl5-29-41L).
The difference in total IgG titers most likely reflects the nature
of the immunogens. The cell lysate viral immunogen prepara-
tion contains substantially more viral protein than supernatant
virus and it was not unexpected that this immunogen raised
much higher total virus-specific antibody titers than the extra-
cellular supernatant viral preparation at equivalent doses.
Neutralizing antibody titers
Neutralizing antibody titers were determined using sera
pooled from the indicated immunization groups of eight mice
each. Balb/c mice immunized with dl5-29-41L showed an 8-fold
increase in the neutralizing antibody titers as compared with
animals immunized with dl5-29. The magnitudes of these
responses were equal regardless of the immunogen preparation
(Table 1). This indicated that the production of neutralizing
antibody was proportional to the number of infectious viral
particles used to immunize mice, not the total amount of antigen,
as with the total HSV-2 specific IgG antibody titers measured by
ELISA.
dl5-29-41L elicits stronger cellular immune responses than
dl5-29
C57Bl/6 or Balb/c mice were immunized twice, subcutane-
ously, with 106 pfu of dl5-29 or dl5-29-41L at an interval of 3
weeks and HSV-specific T-cell responses were measured by two
independent assays. CD8+ T-cell responses were measured
using the highly immunodominant H-2Kb restricted, HSV gBepitope, SSIEFARL, the only well-characterized HSV-specific
CD8+ T-cell epitope (Wallace et al., 1999). These responses
were analyzed using both MHC-I pentamer (ProImmune,
Oxford, UK) staining and intracellular cytokine staining. The
CD4+ T-cell response was measured using the recently
identified H-2d restricted, HSV-2 gD-specific CTL epitope
KPPYTSTLLPPELSD (Cooper et al., 2006) by intracellular
cytokine staining.
MHC-I pentamer staining
HSV gB-SSIEFARL peptide-specific, circulating CD8+ T-cells
in immunized C57Bl/6 mice were quantified using MHC-I
pentamers. dl5-29-41L consistently elicited a stronger response
than dl5-29 with a statistically significant difference seen at the
peak responses (Fig. 3A). The primary response peaked at
7 days post-immunization with dl5-29-41L showing a 2.1-fold
higher response (p≤0.05) than dl5-29 when mice were immu-
nized with lysate virus and 2.3-fold higher response ( p≤0.05)
elicited by dl5-29-41L over dl5-29 when mice were immunized
with supernatant virus. After boosting at day 21 there was also a
transient increase in the number of gB-specific CD8+ T cells
(Fig. 3A). The secondary responses peaked at 6 days post-boost
with dl5-29-41L eliciting a 1.7-fold higher response ( p≤0.05)
in mice immunized with lysate virus and a 2.8-fold increase
( p≤0.05) in mice immunized with supernatant virus. Raw data
of representative samples from the MHC-I pentamer staining
experiment are shown as dot plot graphs allowing visualization
of the separation of cell populations (Supplementary Figure,
panel A).
Intracellular cytokine staining
At 7 days post-boost, mice were sacrificed and splenocytes
were collected. CD8+ responses were measured in C57Bl/6
mice, and CD4+ responses were measured using Balb/c mice.
The percentages of CD8+ splenocytes that specifically produced
IFN-γ when stimulated with the HSV gB-specific peptide
SSIEFARL were measured. This assay verified the MHC-I
pentamer results in that dl5-29-41L induced a statistically sig-
nificantly stronger CD8+ T-cell response than dl5-29 regardless
of the immunogen preparation, showing a 2.6-fold (p≤0.05)
and 4.1-fold (p≤0.05) increase seen in mice immunized with
lysate virus and supernatant virus, respectively (Fig. 3B). The
Fig. 4. Time line for immunization/challenge study. Balb/c mice were
immunized subcutaneously, at 0 and 3 weeks, with varying doses of virus. At
4 weeks post-boost mice were challenged intravaginally with the equivalent of
50 times the lethal dose50 (50 LD50) of wild-type HSV-2 strain G. Vaginal swabs
were collected daily for the first 5 days post-challenge to determine the level of
viral shedding from the site of infection. Mice were followed for 30 days to
determine protection rates.
Fig. 3. dl5-29-41L virus elicits significantly stronger CD4+ and CD8+ cellular immune responses than dl5-29 virus. (A) MHC-I pentamer staining. C57Bl/6 mice were
immunized with dl5-29, dl5-29-41L, uninfected V5-29 cell lysate or PBS+15% glycerol. Whole blood was collected via tail vein bleed, red blood cells were lysed,
and cells were stained with MHC-I pentamers specific for the H2Kb restricted HSV-2 gB immunodominant epitope SSIEFARL and antibody against murine CD8a.
Results are shown as the percentage of CD8+ cells that are also positive for MHC-I pentamer staining ±SEM over time. ⁎pb0.05 for dl5-29 vs dl5-29-41L for both
supernatant and lysate preparations.. (B) CD8+ intracellular cytokine staining. C57Bl/6 mice were immunized twice with dl5-29, dl5-29-41L, uninfected V5-29 cell
lysate or PBS+15% glycerol. At 7 days after boosting, splenocytes were collected and stimulated with the gB-SSIEFARL peptide. Results are shown as the percentage
of CD8+ cells that express IFN-γ specifically after stimulation with the gB-SSIEFARL peptide ±SEM. ⁎p=0.03, ⁎⁎p=0.04. (C) CD4+intracellular cytokine staining.
Balb/c mice were immunized twice with dl5-29, dl5-29-41L, uninfected V5-29 cell lysate or PBS+15% glycerol. At 7 days after boosting, splenocytes were collected
and stimulated with the HSV-2 gD Balb/c specific peptide-KPPYTSTLLPPELSD. Results are shown as the percentage of CD4+ cells that express IFN-γ specifically
after stimulation with the gD peptide ±SEM. ⁎p=0.03, ⁎⁎p=0.04.
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gD-specific CTL epitope KPPYTSTLLPPELSD (Cooper et al.,
2006). The percentage of CD4+ splenocytes that specifically
produced IFN-γ when stimulated with this peptide was also
significantly stronger in mice immunized with dl5-29-41L than
dl5-29, with a 1.7-fold (p≤0.05) or a 4.6-fold (p≤0.05) increase
when mice were immunized with lysate or supernatant viral
preparations respectively (Fig. 3C). Raw data of representative
samples from the intracellular cytokine staining experiment are
shown as dot plot graphs allowing visualization of the separation
of cell populations (Supplementary Figure, panels B, C).
dl5-29-41L elicited stronger protective immunity than dl5-29
against an HSV-2 G strain challenge
To compare the protective immunity induced by the two
viruses, we immunized 8 female Balb/c mice per group, twice,
with either extracellular virus or lysate virus immunogens at 0
and 3 weeks with varying doses (104, 105 or 106 pfu/dose) of the
dl5-29 or dl5-29-41L viruses. At 1 month post-boost, mice were
challenged intravaginally with 5×105 pfu of the wild-type
HSV-2 G strain, a dose equal to 50 times the lethal dose50
(50 LD50) (Fig. 4). As a quantitative measure of viral replication,
we assessed the levels of viral shedding from the vaginal cavity.Vaginal swabs were taken every 24 h post-challenge for 1 week,
and the amount of virus captured was assessed by plaque assay.
Clinical disease
Mice immunized with dl5-29-41L showed less severe signs
of clinical disease than those immunized with dl5-29 for mice
immunized with either supernatant virus (Fig. 5A) or lysate
virus (Fig. 5B). Mice immunized with lysate virus preparations
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41L at a dose of 106 pfu showed no signs of clinical disease.
Protection from paralysis
There was a significant increase in the 30-day protection
rates of mice immunized with dl5-29-41L over those immu-
nized with dl5-29, this being the case whether mice were
immunized with extracellular supernatant (Fig. 5C) or cell
lysate viral (Fig. 5D) immunogens. The increased protection
was quantified through calculation of protective dose 50 (PD50)
values for these immunogens, the dose of vaccine virus needed
for the protection of 50% of the mice from paralysis. As
extracellular virus immunogens, dl5-29-41L had a PD50
calculated to be 15× lower than that of dl5-29 (4×104 pfu vs.
6×105 pfu, respectively), while for the lysate viral immuno-
gens, dl5-29-41L had a PD50 calculated to be 4× lower than that
of dl5-29 (1×104 pfu vs. 4×104 pfu, respectively).
Shedding of challenge virus
Levels of viral shedding peaked at day 2 post-challenge and
then declined steadily over the next 5 days. The effects ofFig. 5. Mice immunized with dl5-29-41L virus have lower clinical disease scores an
intravaginally with a highly lethal dose of wild-type HSV-2 strain G. (A) Clinical dis
disease scores of mice immunized with lysate viral immunogen. (C) Rates of prote
supernatant viral immunogen. (D) Rates of protection from encephalitis in mice im
shedding in the genital tract. Vaginal swabs were taken daily for 7 days post-challenge
shedding from the vaginal tract peaked at day 2 post-challenge. Shown here is the d
immunized with lysate viruses. ⁎⁎pb0.05 between mice immunized with lysate viruimmunization on the duration of viral shedding paralleled the
effects seen on peak viral shedding (data not shown). Peak levels
of viral shedding are shown here as a function of immunogen
dose (Fig. 5E). Mice immunized with dl5-29-41L showed a
greater reduction in the amount of virus being shed from the
vaginal tract when compared to mice immunized with dl5-29 at
all doses administered. The magnitude of the difference in viral
shedding increased with increasing doses of immunizing virus.
Combining the results from both supernatant and lysate viral
immunization groups, mice immunized with 104 pfu of dl5-29-
41L showed an average of 2.4-fold less virus shed from the
vaginal tract compared with those mice immunized with dl5-29,
while mice immunized with 105 pfu showed a 6.1-fold average
reduction in viral shedding and mice immunized with 106 pfu
showed a 7.0-fold average reduction. Mice immunized with
lysate viral immunogen showed a significantly reduced level of
viral shedding as compared with mice immunized with
supernatant virus regardless of dose. This difference peaked at
over a 100-fold decrease in viral shedding in mice immunized
with dl5-29-41L at a dose of 106 pfu. Thus, over a range of
doses, dl5-29-41L elicited greater protective immunity than dl5-d higher rates of protection than those immunized with dl5-29 when challenged
ease scores of mice immunized with extracellular viral immunogen. (B) Clinical
ction from encephalitis in mice immunized with varying doses of extracellular
munized with varying doses of whole cell lysate viral immunogen. (E) Viral
. Viral shedding was determined by standard plaque assay and the levels of virus
ay 2 viral shedding for different doses of immunogen. ⁎pb0.05 between mice
ses and between mice immunized with supernatant viruses.
Fig. 6. Durability of protective immunity. Female Balb/c mice were immunized
at 0 and 3 weeks with 105 pfu of lysate viral immunogen or mock-infected V5-
29 cell lysate. Groups of 8 Balb/c mice were challenged intravaginally with 50
LD50 of the wild-type HSV-2 strain G at 1, 4 or 7 months after boost. Vaginal
swabs were taken daily for 7 days post-challenge and viral shedding was
determined by standard plaque assay. Shown here is the day 2 viral shedding ±
SEM. ⁎p=0.02, ⁎⁎p=0.41, ⁎⁎⁎p=0.11, #pb0.00001.
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supernatant viral preparations.
Durability of immune responses elicited by dl5-29
and dl5-29-41L
To examine the durability of the immune responses, groups
of female Balb/c mice were immunized twice, at weeks 0 and 3,
with 105 pfu of dl5-29 or dl5-29-41L lysate virus and
challenged intravaginally with 5×105 pfu (50 LD50) of the
wild-type HSV-2 G strain at 1, 4 or 7 months post-boost.
Immunogenicity
Mice were bled via tail vein at 1 week pre-challenge and the
total serum IgG response against HSV-2 antigen was measured
via ELISA. We detected no reduction in HSV-2 specific anti-
body titers over time with both viruses eliciting a titer of 12,800
(Table 2). The neutralizing antibody responses were determined
as described earlier with dl5-29 and dl5-29-41L eliciting titers
of 256 and 1024 respectively. These titers were also extremely
durable, showing no loss of effectiveness over this 7-month
time period (Table 2). Although the humoral responses elicited
during the “acute infection” experiments, comparing multiple
doses of immunogens, and the “durability of immunity”
experiments were not of equal magnitude (Tables 1 and 2),
the relative levels of the humoral responses elicited by dl5-29
and dl5-29-41L were similar in the two studies, with dl5-29-
41L eliciting 4- to 8-fold higher neutralizing titers than dl5-29.
Shedding of challenge virus
Consistent with the previous results, when challenged at 1
month post-immunization, mice inoculated with dl5-29-41L
showed 8.6-fold less (p=0.02) virus being shed from the
vaginal tract as compared with mice immunized with dl5-29
(Fig. 6). Surprisingly, mice that were challenged at 4 months
post-immunization no longer showed significant differences in
the levels of viral shedding when immunized with dl5-29 or
dl5-29-41L. This lack of difference in viral shedding was also
seen when mice were challenged at 7 months after immuniza-
tion. Although the levels of viral shedding did increase slightly
with an increase in the duration of time between immunization
and challenge, at 7 months after immunization there was still a
highly significant difference in the levels of viral shedding
between mice immunized with dl5-29 or dl5-29-41L and mockTable 2
Durability of humoral immune responses
Immunogen Time post-immunization
1 month 4 months 7 months
Total IgG titer a Mock 100 100 100
dl5-29 12,800 12,800 12,800
dl5-29-41L 12,800 12,800 12,800
Neutralizing Ab titer b Mock b16 b16 b16
dl5-29 256 256 256
dl5-29-41L 1024 1024 1024
a Measured by ELISA against total HSV-2 G strain antigen.
b Measured by plaque reduction assay against HSV-2 G strain.immunized mice (pb0.00001), indicating that the protective
immune response was quite durable.
Protection from paralysis
When mice were challenged at 1 month post-immunization
both dl5-29-41L and dl5-29 gave a 100% (8/8) protection rate.
When challenged at 4 months post-immunization there was an
insignificant difference (pN0.1) with the dl5-29-41L immu-
nized group showing a 100% (8/8) protection rate, while the
dl5-29 group had a protection rate of 75% (6/8). Both groups
of mice showed 100% (8/8) protection rate when challenged at
7 months post-immunization. Therefore, both dl5-29 and dl5-
29-41L induced protective immunity in mice that was durable
for at least 7 months.
Discussion
The HSV-2 dl5-29 replication-defective mutant virus has
been highly protective as a vaccine in both the mouse (Da Costa
et al., 1999, 2000) and guinea pig genital herpes infection model
systems (Hoshino et al., 2005). Inactivation of the UL41 gene
has been shown to increase the immunogenicity of replication-
competent HSV-1 (Walker and Leib, 1998), as well as
replication-defective HSV-1 viruses (Geiss et al., 2000), but
the immunogenicity of UL41 disrupted HSV-2 replication-
defective mutant viruses has not been examined. Here we
determined the effect of disrupting UL41 on immunogenicity in
the context of an HSV-2 replication-defective mutant virus, the
dl5-29 candidate vaccine virus. We observed that dl5-29-4lL
was more immunogenic than the dl5-29 double mutant, stim-
ulating higher neutralizing antibody titers and higher CD4+ and
CD8+ T-cell responses and, ultimately, providing higher levels
of protection against a lethal challenge.
The correlate(s) of protection against HSV infection in
humans have not been defined, but optimal protection most
likely requires both the humoral and cellular arms of the immune
system. Both CD8+ and CD4+ T cells can directly interfere with
viral replication by killing virally infected cells, while CD8+
T cells have also been shown to suppress HSV reactivation by
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Pereira et al., 2000). In both mice and humans HSV-specific
CD4+ and CD8+ T lymphocytes are found at the site of viral
replication, and infiltration of HSV-specific CD8+ T cells and
interferon-gamma (IFN-γ) production correlates with clearance
of virus (Koelle et al., 1998; Liu et al., 2001, 2000).
The importance of antibody in protection against HSV is less
well defined, but protection of neonates from HSV acquisition
suggests that antibody can protect humans against central ner-
vous system infection (Brown et al., 1991), and studies in animal
models have also shown passive immunization both before or
shortly after infection can beneficially affect the outcome of an
HSV infection (Bourne et al., 2002; Morrison et al., 2001).
Theoretically, strong antibody responses may be important in
preventing primary infection of the mucosa or reducing the
number of infecting HSV particles. Humoral immunity may also
be important in reducing viral spread from the site of primary
infection or recurrent outbreaks. While the improved humoral
immune response is encouraging, the increase in cellular
immunity (Fig. 3) is most significant as immunization studies
have shown that the strong elicitation of a Th1 type cellular
immune response is vital for protecting against and controlling
HSV infections in animals (Milligan and Bernstein, 1995;
Morrison and Knipe, 1997).
Potential mechanisms of increased immunogenicity
of dl5-29-41L
Several mechanisms could explain the ability of dl5-29-41L
to elicit stronger humoral and cellular immune responses. First,
this could involve the ability of UL41 to inhibit type-I interferon
responses (Duerst and Morrison, 2004; Murphy et al., 2003), an
important innate mechanism for effectively initiating an anti-
viral response. Type-I interferons can act by directly stimulating
an innate anti-viral response in host cells and by stimulating the
initiation of T-cell responses (Nguyen et al., 2002). In the
absence of the vhs function, infected cells may undergo a more
robust innate response, allowing increased presentation of viral
antigens. Second, lack of vhs function could lead to decreased
viral cytopathic effects, allowing prolonged viral gene expres-
sion and increased antigen presentation, resulting in a more
robust stimulation of an adaptive immune response. Third,
UL41 is required for HSV-specific inhibition of dendritic cell
(DC) maturation (Prechtel et al., 2005; Samady et al., 2003), a
key cell in stimulating and directing the development of adap-
tive immune responses. By relieving the vhs-specific inhibition
of DC maturation, we may be allowing DCs to stimulate a more
robust immune response. DCs have been shown to be efficient
stimulators of CD4+ and CD8+ T lymphocytes and B lym-
phocytes (Adams et al., 2005); thus, they make a likely
candidate for at least part of the increased humoral and cellular
immunogenicity seen with dl5-29-41L. HSV infection of
immature DCs has been shown to inhibit their maturation
(Samady et al., 2003), while infection of mature DCs blocks
their ability to become re-stimulated by antigen and inhibits
their ability to migrate to lymphoid tissue (Prechtel et al., 2005).
It has also been shown that viruses deficient in vhs do not inhibitDC maturation, activation and/or chemotaxis (Prechtel et al.,
2005; Samady et al., 2003). Perhaps dendritic cells that have
taken up or been infected by dl5-29-41L may be allowed to
further mature and directly prime a stronger response than those
infected by dl5-29. Alternatively, in the absence of the vhs
function, infected cells will continue to express cellular proteins
required to undergo the innate antiviral response of apoptosis.
During HSV infection of several cell types, viral immediate
early gene expression induces apoptosis, which is quickly
inhibited by specific viral gene products (Roizman et al., 2007).
Infection of DCs by wild-type HSV-2 causes them to undergo
apoptosis, a process that does not appear to be efficiently
inhibited by viral gene products (Jones et al., 2003; Pollara et
al., 2005). These apoptotic DCs can be taken up by uninfected
bystander DCs, which can then stimulate an immune response
(Bosnjak et al., 2005). More efficient apoptosis of infected host
cells, including dendritic cells, would increase the amount of
material that bystander DCs can take up allowing for an increase
in cross-presentation or indirect priming of an immune
response, a theory supported by recent studies with HSV
(Bosnjak et al., 2005) and Modified Vaccinia Ankara virus
(Chahroudi et al., 2006).
Disruption of UL41 increases the protective capacity of dl5-29
Most importantly, the increased immunogenicity caused by
the disruption of UL41 in dl5-29 led to an increase in protective
efficacy. Protection of mice immunized with dl5-29-41L was
significantly higher than those immunized with dl5-29, as
measured by clinical disease symptoms, viral replication within
the vaginal tract and protection against paralysis. Focusing on
viral shedding, the most quantitative measure of protection in
our model, disruption of UL41 reduced the average level of viral
shedding by up to 7.3-fold. The superior protective efficacy of
dl5-29-41L was seen with both extracellular supernatant virus
and whole cell lysate virus immunogen preparations. Directly
comparing the efficacy of the different immunogen preparations,
we found that lysate virus immunogen is significantly more
protective than extracellular supernatant purified virus immu-
nogen for both mutant viruses, dl5-29 and dl5-29-41L, with a
15-fold and 4-fold decrease in the PD50, respectively. Although
we did not observe any difference in neutralizing antibody titers
between preparations of either virus, we did detect an increase in
the CD4+ and the CD8+ cellular immune response elicited by the
lysate immunogen preparations of both dl5-29 and dl5-29-41L,
suggesting that the viral proteins present in the lysate preparation
may add to the cellular immune response through cross-
presentation mechanisms and/or that the high levels of viral
and cellular proteins present in the inoculum act as an adjuvant,
stimulating a stronger innate response leading to a more robust
adaptive response.
Protective immunity elicited by dl5-29 and dl5-29-41L
is durable
A successful vaccine must elicit immunity that is not only
protective but also long-lived. We show that the protective
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durable. The protective efficacy of both mutant viruses persisted
for at least 7 months post-immunization, protecting mice from
lethal HSV-2 challenge with only a slight decline in the ability to
reduce levels of viral shedding. Unexpectedly, animals that were
challenged at 4 and 7 months after immunization with dl5-29-
41L no longer showed a significant decrease in the levels of viral
shedding from the site of infection over those animals
immunized with dl5-29. Because the neutralizing antibody
response did not wane over this time period, it can be concluded
that it is not solely responsible for the initial increase in
protection provided by dl5-29-41L over dl5-29 shortly after
immunization or the subsequent waning of that protection.
Cellular immunity was not measured at these later time points,
and we can therefore not say anything about the longevity of
these responses.
Conclusions
In summary, these results show that the disruption of theUL41
gene in the context of a replication-defective HSV-2 mutant
virus, dl5-29, significantly improves its immunogenicity and
protective capacity in a murine HSV-2 infection model system.
We show also that a cellular lysate viral immunogen preparation
is significantly more protective than the more purified extracel-
lular supernatant viral preparation, indicating a potential
advantage for the inclusion of viral proteins in a replication-
defective HSV-2 mutant virus vaccine formulation over that of a
vaccine containing only highly purified virus. Finally, we show
that the protective efficacy elicited by either dl5-29 or dl5-29-
41L is not only robust but also durable, protecting mice from
challenge for up to 7 months post-immunization. While dl5-29
has previously been shown to elicit impressive protective
immunity in animal models (Da Costa et al., 1999; Hoshino et
al., 2005), the degree to which this will translate in humans is
unknown. Thus, any improvement in immunogenicity has the
potential to improve its protective efficacy in humans. The
significant improvement seen here warrants further study of
UL41 deficient replication-defective HSV-2 mutant viruses to
evaluate their potential to protect humans prophylactically and
therapeutically against HSV-2 infection.
Materials and methods
Plasmids
To produce the p1941 plasmid, a 2508 bp fragment of wild-
type HSV-2 viral DNA encompassing the entire UL41 gene
locus flanked by NdeI and BamHI restriction enzyme sites was
cloned into the respective restriction enzyme sites on the pUC19
plasmid (Yanisch-Perron et al., 1985). The p1941L plasmid was
then constructed by insertion of a LacZ expression cassette into
a 518 bp deletion (corresponding to nucleotides 92,342–92,860
of HSV-2 strain HG-52) within the UL41 gene locus that was
created by a SacII–SacII digestion followed by blunting the
ends via incubation with the Klenow fragment of E. coli DNA
Polymerase I.Cells and viruses
The wild-type HSV-2 G (Ejercito et al., 1968) and 186 syn+-1
strains (Spang et al., 1983) were propagated on Vero cells
(ATCC CCL-81). Vero cells were also used to measure virus
neutralizing antibody titers. Vero and mouse embryo fibroblasts
(ATCC SCRC-1008) cells were used to analyze protein
expression patterns of various viruses. The dl5-29 and dl5-29-
41L mutant viruses were grown and titered on V5-29 cells, a
Vero derived cell line that expresses the HSV-1 UL29 gene
product, ICP8, and the HSV-2 UL5 gene product when infected
with HSV (Da Costa et al., 2000). The dl5-29-41L virus was
produced by co-transfection of linearized p1941L plasmid
together with sodium iodide gradient purified dl5-29 viral DNA.
Triple mutant viruses, containing the LacZ expression cassette
within theUL41 gene locus, were screened for as blue plaques in
the presence of X-gal as described previously (Da Costa et al.,
1997). Whole cell lysate virus immunogen was obtained by
collecting infected cells and resuspending them in 50% DMEM
culture media and 50% sterile whole milk followed by a single
freeze–thaw cycle and sonication to disrupt cellular membranes
and other coagulates. Extracellular supernatant virus immuno-
gen was collected by removal of cells and cellular debris from
culture supernatants via low-speed centrifugation and virus was
then concentrated by ultracentrifugation and resuspended in
PBS–15% glycerol and sonicated.
Animal studies
Animal housing and experiments were conducted as per
protocols approved by the Harvard Medical Area Standing
Committee on Animals.
(i) Immunogenicity studies. Five-week-old female C57Bl/6
or Balb/c mice (Taconic Farms) were immunized twice,
subcutaneously, 3 weeks apart, in the rear flank with
1×106 plaque forming units (pfu) in a 50 μl volume of
either extracellular supernatant virus or cell lysate virus
immunogen.
(ii) Challenge studies. Five-week-old female Balb/c mice
(Taconic Farms) were immunized twice, subcutaneously,
3 weeks apart, in the rear flank with varying amounts of
extracellular supernatant virus or cell lysate virus (104,
105 or 106 pfu) in a 50 μl volume. At 1, 4 or 7 months
after the second immunization the vaginal cavity was
pre-swabbed with a wet dacron swab (PurFybr, Munster,
IN) and mice were challenged intravaginally with the
wild-type HSV-2 G strain equivalent to 50 times the
LD50 (5.0×10
5 pfu) in a 25 μl volume using a micro-
pipettor as described (Morrison et al., 1998). Protective
dose 50's (PD50) were calculated using the Reed-Muench
method.
Antibody titers
At 7 days post-immunization mice were bled via the tail
vein, and sera were prepared using Microtainer tubes (BD
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Total HSV-2 specific IgG antibody titers were determined by
ELISA as described previously (Da Costa et al., 2000). Briefly,
96-well MaxiSorb plates (Nalge NUNC, Rochester NY) were
coated with HSV-2 G strain viral lysate (Advanced Biotech-
nologies Inc., Columbia, MD) at 50 ng per well in 0.05 M
carbonate–bicarbonate buffer (pH 9.6) (Sigma-Aldrich, St.
Louis, MO) overnight at 4 °C. Plates were blocked with PBS
containing 5% milk at 37 °C for 1 h, washed three times with
PBS containing 0.05% Tween-20 (PBS T-20) and incubated
with serial two-fold dilutions of mouse sera, in triplicate, for 4 h
at 37 °C. Plates were then washed three times with PBS T-20
and incubated with goat anti-mouse IgG antibody conjugated
with alkaline phosphatase (1:1000 in PBS T-20; Sigma-Aldrich)
for 1 h at 37 °C. The plates were then washed three times
with PBS T-20. Finally, SigmaFast p-nitrophenyl phosphate
(Sigma-Aldrich) was used to develop a colored product, and the
optical density was detected at 405 nm using a microplate reader
(Molecular Devices, Union City, CA). Antibody titers are
reported as the reciprocal of the final dilution that resulted in an
absorbance value 0.2 higher than mock immunized mouse sera
or, for mock immunized mouse sera, an absorbance value 0.2
higher than background. Total serum IgG titers were determined
through three independent experiments, each time in triplicate.
Neutralizing antibody titers
Neutralizing antibody titers were determined using a stan-
dard plaque reduction assay. Mouse sera were heat-inactivated
for 30 min at 56 °C, and neutralizing antibody titers were
determined against the HSV-2 G strain. One hundred plaque-
forming units of virus was incubated with two-fold serial
dilutions of sera for 90 min at 37 °C in a 1:8 dilution of
LowTox-H Rabbit complement (Cedarlane, Burlington, NC) in
DMEM. The incubated mixtures were then added, in triplicate,
to Vero cell monolayers in 6-well plates for a 1-h incubation at
37 °C. The inocula were removed and replaced with DMEM
containing 1% bovine calf serum, penicillin/streptomycin and
0.5% pooled human immunoglobulin G (Massachusetts Public
Health Biologic Laboratories, Boston, MA). After 48 h the
plates were fixed with methanol, stained with Giemsa stain, and
plaques were counted. The neutralizing antibody titer is
reported as the reciprocal of the highest dilution of serum
resulting in at least a 50% reduction in the number of plaques, as
compared to those incubated with sera from mock immunized
mice. Neutralizing titers were determined through three
independent experiments, each time in triplicate.
MHC-I pentamer staining of HSV gB specific CD8+ T cells
Whole blood samples, approximately 35 μl, were collected
via tail vein bleed. Red blood cells were lysed using RBC Lysis
Buffer (eBioscience, San Diego, CA). White blood cells were
resuspended in 20 μl PBS, 1% BSA, 0.1% sodium azide and
incubated with 5 μl of HSV gB SSIEFARL peptide-specific
MHC-I pentamers (Proimmune Ltd., Oxford, United Kingdom)
at room temperature for 15 min. Cells were washed and thenstained with antibodies against murine CD8a at 4 °C for 30 min.
Samples were analyzed by flow cytometry. Results are
expressed as the percentage of CD8a positive cells that stain
positive for the gB-specific MHC-I pentamer.
Intracellular cytokine staining
Splenocytes from immunized C57Bl/6 or Balb/c mice were
harvested at 7 days post-immunization. To analyze the CD8+
cellular immune response, 1×106 cells were incubated with
the H2Kb-specific HSV gB peptide SSIEFARL (10 ng/ml).
Negative controls were stimulated with the H2Kb-specific
OVA peptide SIINFEKL (10 ng/ml). To measure the CD4+
cellular immune responses, splenocytes from Balb/c mice were
incubated with the HSV gD peptide KPPYTSTLLPPELSD
(10 ng/ml). The splenocytes were then placed in a 37 °C, 5%
CO2 humidified incubator for 1 h, at which point Brefeldin A
was added, and cells were incubated for 4 h. Cells were
stained with antibodies against murine CD8a or CD4 for 1 h
then fixed with 1% formaldehyde in PBS, permeabilized in
PBS+0.2% saponin and stained with antibodies for IFN-γ
for 16 h at 4 °C. Samples were analyzed via flow cytometry.
Results are expressed as the percentage of cells staining
positively for CD8a or CD4 that also stain positive for IFN-γ
when stimulated with the gB or gD-specific peptides. Results
from negative controls have been subtracted from the
experimental values listed.
Assay of acute infection
Every 24 h post-intravaginal challenge the vaginal cavities of
the mice were swabbed with pre-wetted dacron swabs (PurFybr)
twice successively. The swabs were placed in 1 ml of assay
medium (PBS, 0.1% Glucose, 1% FCS) and stored at −80 °C.
Viral titers were determined by standard plaque assay.
Clinical observations
Wild-type HSV-2 infected mice were observed daily for signs
of genital lesions and systemic illness. The severity of disease was
scored as follows: 0=no sign of disease; 1=slight genital ery-
thema and edema; 2=moderate genital inflammation; 3=purulent
genital lesions; 4=hind-limb paralysis (Morrison et al., 1998).
Mice were euthanized using CO2 at the first sign of paralysis.
Statistical analysis
All statistical analysis was performed using two-sided
Student's t-tests.
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